Mezzion Pharma Co.,Ltd.

A140410

KR7140410002

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
39,200 ^KRW	+6.52%		+5.38%	+0.51%

Mar. 18	Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Tranche Update on Mezzion Pharma Co.,Ltd.'s Equity Buyback Plan announced on April 6, 2015.

April 28, 2015

From April 6, 2015 to April 28, 2015, the company has repurchased 106,007 shares, representing 1.39% for KRW 2,932.31 million. With this, the company has completed the repurchase of 106,007 shares, representing 1.39% for KRW 2,932.31 million under the buyback announced on April 6, 2015.

Latest news about Mezzion Pharma Co.,Ltd.

Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Mezzion Pharma Co.,Ltd. announced that it has received KRW 49.99999719 billion in funding from BRV Capital Management and other investors	23-06-19	CI
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14	CI
Mezzion Pharma to Raise 50 Billion Won From Share Sale	23-04-19	MT
Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 49.99999719 billion in funding from BRV Capital Management	23-04-18	CI
Mezzion Pharma Co.,Ltd. Submits Protocol for Confirmatory Pivotal Phase 3 Trial ("FUEL-2") in Fontan Subjects	23-02-21	CI
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Mezzion Pharma Co.,Ltd. Receives Clear FDA Path Forward for the Approval of Udenafil for Single Ventricle Heart Disease	22-05-31	CI
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI
Mezzion Pharma Announces Positive Data Presented to FDA in Type C Meeting	21-12-21	CI
Mezzion Pharma Co.,Ltd. announced that it has received KRW 20 billion in funding	21-11-15	CI
Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 20 billion in funding	21-11-11	CI
Mezzion Appoints William Breitenbach as Chief Commercial Officer for Mezzion's Global Commercial Operations	21-06-15	CI
Mezzion's New Drug Application for Its Orphan Drug Udenafil for the Treatment of Single Ventricle Heart Disease Has Been Accepted for Filing by the FDA	21-05-25	CI
Mezzion Pharma Co. Ltd. Announces Re-Submission of New Drug Application for its Orphan Drug Udenafil	21-03-28	CI
Mezzion Pharma Co. Ltd. Announces Submission of New Drug Application for its Orphan Drug Udenafil to Treat Patients	20-06-30	CI
Mezzion Pharma's Announces Results from the Pivotal 400-Subject Phase 3 Fuel Trial	20-05-18	CI
Mezzion Pharma Announces the Presentation of the FUEL Trial Data at the American Heart Association Meeting in Philadelphia	19-11-17	CI
Mezzion Pharma Co.,Ltd. Announces Top Line Data from FUEL Will Be Presented at the American Heart Association, Late Breaking Scientific Sessions, in Philadelphia, PA, November 17, 2019	19-11-04	CI
Mezzion Pharma Co.,Ltd. Announces Positive Results from the Fontan Udenafil Exercise Longitudinal Trial, in Adolescents with Single Ventricle Heart Disease Who Have Undergone the Fontan Procedure	19-07-30	CI
Mezzion Pharma Co.,Ltd. announced that it has received KRW 15 billion in funding from a group of investors	16-09-04	CI
Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 15 billion in funding from a group of investors	16-08-31	CI

Chart Mezzion Pharma Co.,Ltd.

Duration

Period

More charts

Company Profile

Mezzion Pharma Co., Ltd. is a Korea-based company engaged in the pharmaceutical business. The Company focuses on development and manufacture of remedies for erectile dysfunction and benign prostatic hyperplasia. In addition, the Company engages in the development of remedies for portal hypertension (PH), pulmonary arterial hypertension (PAH), overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and others. The Company has sighed licensing contract with overseas partners, including Warner in America, Valenta in Russia, Nycomed in Mexico and Dr.Falk in Europe. On April 22, 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MEZZION PHARMA CO.,LTD.	+0.51%	848M
KYOWA KIRIN CO. LTD.	+11.94%	9.18B
SK BIOPHARMACEUTICALS CO., LTD.	-16.33%	4.79B
YUHAN CORPORATION	+6.40%	3.97B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+26.98%	3.98B
INDIVIOR PLC	+28.27%	2.56B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-26.55%	2.29B
BETTA PHARMACEUTICALS CO., LTD.	-25.02%	2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+5.82%	1.92B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B